Locally Aggressive Connective Tissue Tumors

被引:56
作者
Gounder, Mrinal M. [1 ,2 ]
Thomas, David M. [3 ]
Tap, William D. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Sch, New York, NY USA
[3] Garvan Inst Med Res, Darlinghurst, NSW, Australia
关键词
GIANT-CELL TUMOR; DESMOID-TYPE FIBROMATOSIS; VILLONODULAR SYNOVITIS; PHASE-II; EFFICACY; BONE; IMATINIB; EXPRESSION; DENOSUMAB; METHOTREXATE;
D O I
10.1200/JCO.2017.75.8482
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this review, we highlight the complexities of the natural history, biology, and clinical management of three intermediate connective tissue tumors: desmoid tumor (DT) or aggressive fibromatosis, tenosynovial giant cell tumor (TGCT) or diffuse-type pigmented villonodular synovitis (dtPVNS), and giant cell tumor of bone (GCTB). Intermediate histologies include tumors of both soft tissue and bone origin and are locally aggressive and rarely metastatic. Some common aspects to these tumors are that they can be locally infiltrative and/or impinge on critical organs, which leads to disfigurement, pain, loss of function and mobility, neurovascular compromise, and occasionally life-threatening consequences, such as mesenteric, bowel, ureteral, and/or bladder obstruction. DT, PVNS, and GCTB have few and recurrent molecular aberrations but, paradoxically, can have variable natural histories. A multidisciplinary approach is recommended for optimal management. In DT and PVNS, a course of observation may be appropriate, and any intervention should be guided by symptoms and/or disease progression. A surgical approach should take into consideration the infiltrative nature, difficulty in obtaining wide margins, high recurrence rates, acute and chronic surgical morbidities, and impact on quality of life. There are similar concerns with radiation, which especially relate to optimal field and transformation to high-grade radiation-associated sarcomas. Systemic therapies must be considered carefully in light of acute and chronic toxicities. Although standard and novel therapies are promising, many unanswered questions, such as duration of therapy and optimal end points to evaluate efficacy of drugs in clinical practice and trials, exist. Predictive biomarkers and novel clinical trial end points, such as volumetric measurement, magnetic resonance imaging T2 weighted mapping, nuclear imaging, and patient-reported outcomes, are in development and will require validation in prospective trials. (c) 2017 by American Society of Clinical Oncology
引用
收藏
页码:202 / +
页数:9
相关论文
共 54 条
  • [1] [Anonymous], 2013, INT AGENCY RES CANC
  • [2] Expression of osteoclast differentiation signals by stromal elements of giant cell tumors
    Atkins, GJ
    Haynes, DR
    Graves, SE
    Evdokiou, A
    Hay, S
    Bouralexis, S
    Findlay, DM
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (04) : 640 - 649
  • [3] Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
    Behjati, Sam
    Tarpey, Patrick S.
    Presneau, Nadege
    Scheipl, Susanne
    Pillay, Nischalan
    Van Loo, Peter
    Wedge, David C.
    Cooke, Susanna L.
    Gundem, Gunes
    Davies, Helen
    Nik-Zainal, Serena
    Martin, Sancha
    McLaren, Stuart
    Goodie, Victoria
    Robinson, Ben
    Butler, Adam
    Teague, Jon W.
    Halai, Dina
    Khatri, Bhavisha
    Myklebost, Ola
    Baumhoer, Daniel
    Jundt, Gernot
    Hamoudi, Rifat
    Tirabosco, Roberto
    Amary, M. Fernanda
    Futreal, P. Andrew
    Stratton, Michael R.
    Campbell, Peter J.
    Flanagan, Adrienne M.
    [J]. NATURE GENETICS, 2013, 45 (12) : 1479 - U105
  • [4] Desmoid Tumors and Celecoxib with Sorafenib
    Benech, Nicolas
    Walter, Thomas
    Saurin, Jean-Christophe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (26) : 2595 - 2597
  • [5] Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT)
    Blay, J. -Y.
    El Sayadi, H.
    Thiesse, P.
    Garret, J.
    Ray-Coquard, I.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (04) : 821 - U1
  • [6] Boers-Doets CB, 2013, J CLIN ONCOL, V31
  • [7] Extra-abdominal primary fibromatosis:: Aggressive management could be avoided in a subgroup of patients
    Bonvalot, S.
    Eldweny, H.
    Haddad, V.
    Rimareix, F.
    Missenard, G.
    Oberlin, O.
    Vanel, D.
    Terrier, P.
    Blay, J. Y.
    Le Cesne, A.
    Le Pechoux, C.
    [J]. EJSO, 2008, 34 (04): : 462 - 468
  • [8] Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought
    Bonvalot, Sylvie
    Ternes, Nils
    Fiore, Marco
    Bitsakou, Georgina
    Colombo, Chiara
    Honore, Charles
    Marrari, Andrea
    Le Cesne, Axel
    Perrone, Federica
    Dunant, Ariane
    Gronchi, Alessandro
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (13) : 4096 - 4102
  • [9] Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis
    Brahmi, Mehdi
    Vinceneux, Armelle
    Cassier, Philippe A.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (02) : 1 - 9
  • [10] Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone
    Branstetter, Daniel G.
    Nelson, Scott D.
    Manivel, J. Carlos
    Blay, Jean-Yves
    Chawla, Sant
    Thomas, David M.
    Jun, Susie
    Jacobs, Ira
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (16) : 4415 - 4424